
特瑞普利单抗联合阿昔替尼一线治疗晚期肾细胞癌的成本-效果分析
Cost-utility Analysis of Toripalimab Plus Axitinib in the First-line Treatment of Advanced Renal Cell Carcinoma
{{custom_ref.label}} |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
/
〈 |
|
〉 |